Pub Date : 2025-01-31DOI: 10.1016/j.hermed.2025.100993
Siddig Ibrahim Abdelwahab , Manal Mohamed Elhassan Taha , Syam Mohan
Introduction
This study evaluated the available literature concerning the diverse aspects of natural product activity against leukaemia.
Methods
Bibliometric data were obtained from the Scopus bibliographic database through search phrases developed from the MeSH database. Statistical analysis of the data was performed via Bibliometerix and VOSviewer. The search query was constructed on the basis of MeSH terms (D010936, D064209, and D007938) for the major topics. The data were further examined via bibliometric software tools such as Bibliometerix and VOSviewer.
Results
This bibliometric assessment covered original scientific articles from 1961 to 2023 in 1 039 journals and 4 704 documents with positive trends, which suggested a polynomial regression fit of the data (R² = 0.9346). The most active researcher is T. Efferth (Germany). The most advanced, cited, and collaborative nation is the United States. The key themes identified include ‘apoptosis,’ ‘cancer,’ ‘cytotoxicity,’ ‘HL-60 cells,’ and ‘Bcl-2.’ Thematic evolution reveals a shift toward emerging areas such as ‘molecular docking’ and ‘network pharmacology.’
Conclusions
These findings provide critical insights into research trends and highlight the evolving focus within leukaemia-related natural product studies, offering directions for future advancements.
{"title":"Natural Products in Leukaemia Research: A Bibliometric Review","authors":"Siddig Ibrahim Abdelwahab , Manal Mohamed Elhassan Taha , Syam Mohan","doi":"10.1016/j.hermed.2025.100993","DOIUrl":"10.1016/j.hermed.2025.100993","url":null,"abstract":"<div><h3>Introduction</h3><div>This study evaluated the available literature concerning the diverse aspects of natural product activity against leukaemia.</div></div><div><h3>Methods</h3><div>Bibliometric data were obtained from the Scopus bibliographic database through search phrases developed from the MeSH database. Statistical analysis of the data was performed via Bibliometerix and VOSviewer. The search query was constructed on the basis of MeSH terms (D010936, D064209, and D007938) for the major topics. The data were further examined via bibliometric software tools such as Bibliometerix and VOSviewer.</div></div><div><h3>Results</h3><div>This bibliometric assessment covered original scientific articles from 1961 to 2023 in 1 039 journals and 4 704 documents with positive trends, which suggested a polynomial regression fit of the data (R² = 0.9346). The most active researcher is T. Efferth (Germany). The most advanced, cited, and collaborative nation is the United States. The key themes identified include ‘apoptosis,’ ‘cancer,’ ‘cytotoxicity,’ ‘HL-60 cells,’ and ‘Bcl-2.’ Thematic evolution reveals a shift toward emerging areas such as ‘molecular docking’ and ‘network pharmacology.’</div></div><div><h3>Conclusions</h3><div>These findings provide critical insights into research trends and highlight the evolving focus within leukaemia-related natural product studies, offering directions for future advancements.</div></div>","PeriodicalId":56077,"journal":{"name":"Journal of Herbal Medicine","volume":"50 ","pages":"Article 100993"},"PeriodicalIF":2.2,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143421532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Non-alcoholic fatty liver disease (NAFLD) is a prevalent metabolic disorder. Its emergence as a major health challenge has prompted a re-evaluation of therapeutic approaches, particularly considering the limitations associated with prevailing conventional treatments. It was hypothesized that Habb-e-Ghafis may exhibit therapeutic properties capable of ameliorating the pathological processes associated with NAFLD. The aim of the study was to evaluate the safety and efficacy of Habb-e-Ghafis in the treatment of non-alcoholic fatty liver disease.
Methods
This was a single-blind, randomised, standard-controlled clinical study. The study involved 44 non-alcoholic fatty liver disease patients, with 42 completing the trial. The study was approved by the Institutional Ethics Committee (IEC No.: RRIUMSGR/ MD-2019/CT/HG/NAFLD) on November 26, 2021, and registered with the Clinical Trials Registry-India (CTRI/2022/01/039497) on January 17, 2022. Patient recruitment commenced in March 2022 at RRIUM Hospital. The test group (22 patients) received Habb-e-Ghafis (3 pills, thrice daily) for 45 days, while the control group (22 patients) received Vitamin E (400 mg twice daily).
Results
Our study revealed the remarkable effectiveness of Habb-e-Ghafis in alleviating subjective symptoms. It significantly reduced liver span as quantified by Ultrasonography when compared to the standard medication. Concerning lipid profiles, the experimental drug notably reduced triglycerides and very low-density lipoprotein levels in comparison to the standard drug. Other lipid parameters showed similar effects in both treatment groups.
Conclusions
The results of this study suggest that Habb-e-Ghafis is more effective than the standard drug Vitamin E at reducing both subjective and objective parameters.
{"title":"Evaluating the Therapeutic Efficacy of Habb-e-Ghafis in Non-alcoholic Fatty Liver Disease, a Randomised, Single-Blind, Standard-Controlled Trial","authors":"Nida Mehraj, Zaffar Hussain, Atiba Jan, Zarfah Fida","doi":"10.1016/j.hermed.2024.100986","DOIUrl":"10.1016/j.hermed.2024.100986","url":null,"abstract":"<div><h3>Introduction</h3><div>Non-alcoholic fatty liver disease (<strong>NAFLD</strong>) is a prevalent metabolic disorder. Its emergence as a major health challenge has prompted a re-evaluation of therapeutic approaches, particularly considering the limitations associated with prevailing conventional treatments. It was hypothesized that <em>Habb-e-Ghafis</em> may exhibit therapeutic properties capable of ameliorating the pathological processes associated with NAFLD. The aim of the study was to evaluate the safety and efficacy of <em>Habb-e-Ghafis</em> in the treatment of non-alcoholic fatty liver disease.</div></div><div><h3>Methods</h3><div>This was a single-blind, randomised, standard-controlled clinical study. The study involved 44 non-alcoholic fatty liver disease patients, with 42 completing the trial. The study was approved by the Institutional Ethics Committee (IEC No.: RRIUMSGR/ MD-2019/CT/HG/NAFLD) on November 26, 2021, and registered with the Clinical Trials Registry-India (CTRI/2022/01/039497) on January 17, 2022. Patient recruitment commenced in March 2022 at RRIUM Hospital. The test group (22 patients) received <em>Habb-e-Ghafis</em> (3 pills, thrice daily) for 45 days, while the control group (22 patients) received Vitamin E (400 mg twice daily).</div></div><div><h3>Results</h3><div>Our study revealed the remarkable effectiveness of <em>Habb-e-Ghafis</em> in alleviating subjective symptoms. It significantly reduced liver span as quantified by Ultrasonography when compared to the standard medication. Concerning lipid profiles, the experimental drug notably reduced triglycerides and very low-density lipoprotein levels in comparison to the standard drug. Other lipid parameters showed similar effects in both treatment groups.</div></div><div><h3>Conclusions</h3><div>The results of this study suggest that <em>Habb-e-Ghafis</em> is more effective than the standard drug Vitamin E at reducing both subjective and objective parameters.</div></div>","PeriodicalId":56077,"journal":{"name":"Journal of Herbal Medicine","volume":"50 ","pages":"Article 100986"},"PeriodicalIF":2.2,"publicationDate":"2025-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143143989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-06DOI: 10.1016/j.hermed.2024.100985
Rebeca Lachovicz, Vera Ferro-Lebres, Juliana Almeida-de-Souza
Introduction
Approximately 10 million annual deaths may be associated with hypertension. Adverse effects and non-response to pharmacological treatment limit therapy to a significant proportion of patients; hence, treatment alternatives seem necessary. Our objective was to review data about the impact of herbal medicine on reducing blood pressure (BP) in prehypertensive and hypertensive patients.
Methods
A systematic review was conducted (PRISMA guidelines), using PUBMED, SCOPUS, and WEB OF SCIENCE databases, without time restriction. The inclusion criteria were randomised controlled trials and quasi-experimental studies in humans focusing antihypertensive effect of phytotherapeutics: Allium sativum, Apium graveolens, Nigella sativa, Panax ginseng, and Hibiscus sabdariffa on BP in adults with prehypertension or hypertension. The exclusion criteria were the usage of combined medicinal plants. Data about systolic and diastolic BP differences before and after phytotherapy were extracted manually and summarised. The risk of bias was assessed using the JBI tool.
Results
Forty-five studies were selected (15 A sativum, 4 A graveolens, 4 N sativa, 9 P ginseng, and 13 H sabdariffa). Antihypertensive effect was observed for A sativum systolic and diastolic BP (−18.1/−9 mmHg), A graveolens (−37.9/−15.4 mmHg), N sativa (−11.8/−8.8 mmHg), P ginseng (−17.4/−7.1 mmHg), and H sabdariffa (−61.4/−66.2 mmHg).
Discussion/Conclusions
Herbal medicines can reduce high BP levels in prehypertension and hypertension, when used alone or together with lifestyle changes or antihypertensive drugs. Results interpretation is crucial, given the studies quality variation and the discrepancies. More consistent clinical studies in humans are needed to accurately determine efficacy and safety in the treatment of hypertension.
{"title":"Phytotherapy: A Systematic Review for the Treatment of Hypertension","authors":"Rebeca Lachovicz, Vera Ferro-Lebres, Juliana Almeida-de-Souza","doi":"10.1016/j.hermed.2024.100985","DOIUrl":"10.1016/j.hermed.2024.100985","url":null,"abstract":"<div><h3>Introduction</h3><div>Approximately 10 million annual deaths may be associated with hypertension. Adverse effects and non-response to pharmacological treatment limit therapy to a significant proportion of patients; hence, treatment alternatives seem necessary. Our objective was to review data about the impact of herbal medicine on reducing blood pressure (<strong>BP</strong>) in prehypertensive and hypertensive patients.</div></div><div><h3>Methods</h3><div>A systematic review was conducted (PRISMA guidelines), using PUBMED, SCOPUS, and WEB OF SCIENCE databases, without time restriction. The inclusion criteria were randomised controlled trials and quasi-experimental studies in humans focusing antihypertensive effect of phytotherapeutics: <em>Allium sativum</em>, <em>Apium graveolens</em>, <em>Nigella sativa</em>, <em>Panax ginseng</em>, and <em>Hibiscus sabdariffa</em> on BP in adults with prehypertension or hypertension. The exclusion criteria were the usage of combined medicinal plants. Data about systolic and diastolic BP differences before and after phytotherapy were extracted manually and summarised. The risk of bias was assessed using the JBI tool.</div></div><div><h3>Results</h3><div>Forty-five studies were selected (15 <em>A sativum</em>, 4 <em>A graveolens</em>, 4 <em>N sativa</em>, 9 <em>P ginseng</em>, and 13 <em>H sabdariffa)</em>. Antihypertensive effect was observed for <em>A sativum</em> systolic and diastolic BP (−18.1/−9 mmHg), <em>A graveolens</em> (−37.9/−15.4 mmHg), <em>N sativa</em> (−11.8/−8.8 mmHg), <em>P ginseng</em> (−17.4/−7.1 mmHg), and <em>H sabdariffa</em> (−61.4/−66.2 mmHg).</div></div><div><h3>Discussion/Conclusions</h3><div>Herbal medicines can reduce high BP levels in prehypertension and hypertension, when used alone or together with lifestyle changes or antihypertensive drugs. Results interpretation is crucial, given the studies quality variation and the discrepancies. More consistent clinical studies in humans are needed to accurately determine efficacy and safety in the treatment of hypertension.</div></div>","PeriodicalId":56077,"journal":{"name":"Journal of Herbal Medicine","volume":"50 ","pages":"Article 100985"},"PeriodicalIF":2.2,"publicationDate":"2025-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143143988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-05DOI: 10.1016/j.hermed.2025.100990
MacDonald Idu , Susan Omo Okojie , Benjamin Ogunma Gabriel
Introduction
The potential antibacterial properties of aqueous extracts of Ganoderma lucidum, particularly its ability to combat pathogenic bacteria and fungi, have captivated the interest of both the scholarly and pharmaceutical sectors. This investigation was conducted to explore the antimicrobial efficacy of aqueous extracts of G. lucidum: Sample A (subjected to boiling for 1 hour) and Sample B (subjected to boiling for 3 hours) against pathogenic bacteria and yeast.
Method
Standard microbiological procedures were used to isolate, identify, and determine the antimicrobial properties of the extracts. A standard procedure was utilised to prepare the samples.
Results
As evidenced in the study, a notable disparity was observed in the impact of the Sample A extract on the test isolates, with the most pronounced effect noted on Staphylococcus spp at a concentration of 1 000 mg/ml (10.33 ± 0.88 mm). Conversely, no antimicrobial activity (0.00 ± 0.00 mm) was detected in any concentration against E. coli, Enterobacter spp, Bacillus spp, and Candida spp. Moreover, the findings pertaining to Sample B indicated that the most substantial effect was observed on Pseudomonas spp at 1 000 mg/ml (6.67 ± 0.33 mm). Conversely, no antimicrobial efficacy (0.00 ± 0.00 mm) was observed in all concentrations of the extract against Staphylococcus spp and Candida spp, while E. coli, Enterobacter spp, and Bacillus spp exhibited no activity at concentrations of 125 and 62.5 mg/ml.
Conclusion
These findings demonstrate the presence of bioactive substances with a wide range of antibacterial action in G. lucidum confirming assertions of the traditional herbalists that some bacterial diseases in people may be treated with Ganoderma species, hence the need for further study on compound isolation guided bio-assay.
{"title":"In-vitro microbicidal activity of Ganoderma lucidum aqueous extract against selected pathogenic bacteria and yeast","authors":"MacDonald Idu , Susan Omo Okojie , Benjamin Ogunma Gabriel","doi":"10.1016/j.hermed.2025.100990","DOIUrl":"10.1016/j.hermed.2025.100990","url":null,"abstract":"<div><h3>Introduction</h3><div>The potential antibacterial properties of aqueous extracts of <em>Ganoderma lucidum</em>, particularly its ability to combat pathogenic bacteria and fungi, have captivated the interest of both the scholarly and pharmaceutical sectors. This investigation was conducted to explore the antimicrobial efficacy of aqueous extracts of <em>G. lucidum</em>: Sample A (subjected to boiling for 1 hour) and Sample B (subjected to boiling for 3 hours) against pathogenic bacteria and yeast.</div></div><div><h3>Method</h3><div>Standard microbiological procedures were used to isolate, identify, and determine the antimicrobial properties of the extracts. A standard procedure was utilised to prepare the samples.</div></div><div><h3>Results</h3><div>As evidenced in the study, a notable disparity was observed in the impact of the Sample A extract on the test isolates, with the most pronounced effect noted on <em>Staphylococcus</em> spp at a concentration of 1<!--> <!-->000 mg/ml (10.33 ± 0.88 mm). Conversely, no antimicrobial activity (0.00 ± 0.00 mm) was detected in any concentration against <em>E. coli</em>, <em>Enterobacter</em> spp, <em>Bacillus</em> spp, and <em>Candida</em> spp. Moreover, the findings pertaining to Sample B indicated that the most substantial effect was observed on <em>Pseudomonas</em> spp at 1<!--> <!-->000 mg/ml (6.67 ± 0.33 mm). Conversely, no antimicrobial efficacy (0.00 ± 0.00 mm) was observed in all concentrations of the extract against <em>Staphylococcus</em> spp and <em>Candida</em> spp, while <em>E. coli, Enterobacter</em> spp, and <em>Bacillus</em> spp exhibited no activity at concentrations of 125 and 62.5 mg/ml.</div></div><div><h3>Conclusion</h3><div>These findings demonstrate the presence of bioactive substances with a wide range of antibacterial action in <em>G. lucidum</em> confirming assertions of the traditional herbalists that some bacterial diseases in people may be treated with <em>Ganoderma</em> species, hence the need for further study on compound isolation guided bio-assay.</div></div>","PeriodicalId":56077,"journal":{"name":"Journal of Herbal Medicine","volume":"50 ","pages":"Article 100990"},"PeriodicalIF":2.2,"publicationDate":"2025-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143143990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-02DOI: 10.1016/j.hermed.2024.100989
Syamand A. Qadir , Farhang H. Awlqadr , Miran H. Qadir , Sherzad R.A. Tobakari , Aryan M. Faraj , Sahar H. Hamarashid , Tablo H. Salih , Mohammed N. Saeed
Introduction
Throughout history, medicinal plants have been used as essential for humans treatment. The antibacterial applications of tarragon (Artemisia dracunculus) in phytotherapy will be covered in this review study. Despite the advancements in pharmaceuticals, herbal remedies continue to be vital, especially in areas where access to modern therapy is limited. In addition, the antibacterial qualities of Tarragon plant extracts and their innovative extraction techniques are described in this review article.
Methods
A thorough examination of the literature looked at the chemical composition, historical uses, and modern extraction techniques of tarragon (A. dracunculus). The extraction techniques, such as the in-syringe reversed dispersive liquid-liquid microextraction (IS-R-DLLME), ultrasound-assisted extraction (UAE), deep eutectic solvents (DES), and pressurised liquid extraction (PLE), and the methods of review analysis the antibacterial properties of tarragon (A. dracunculus) extracts against dangerous microbes.
Results
Both Gram-positive and Gram-negative bacteria can be effectively resistant by tarragon (A. dracunculus) essential oils and extracts. Also the primary bioactive components were limonene, methyl eugenol, and estragole. The yield and purity of bioactive components were enhanced by novel extraction techniques such as IS-R-DLLME and UAE. At minimum inhibitory concentrations (MIC). Therefore, the essential oils demonstrated strong antibacterial action against Escherichia coli and Staphylococcus aureus.
Discussion/Conclusions
The tarragon (A. dracunculus) plant may be regarded as a potent natural antibacterial agent, especially for antibiotic-resistant illnesses. By combining traditional botanical knowledge with contemporary extraction methods, new medicinal compounds can be created. This study highlighted the need to explore the synergistic effects of tarragon's bioactive components and improve extraction methods in order to optimise therapeutic advantages. Ultimately, tarragon (A. dracunculus) may help antibiotic resistance and microbial illnesses.
{"title":"Bioactivities, medicinal properties, and advanced extraction techniques of Tarragon (Artemisia dracunculus): a comprehensive review","authors":"Syamand A. Qadir , Farhang H. Awlqadr , Miran H. Qadir , Sherzad R.A. Tobakari , Aryan M. Faraj , Sahar H. Hamarashid , Tablo H. Salih , Mohammed N. Saeed","doi":"10.1016/j.hermed.2024.100989","DOIUrl":"10.1016/j.hermed.2024.100989","url":null,"abstract":"<div><h3>Introduction</h3><div>Throughout history, medicinal plants have been used as essential for humans treatment. The antibacterial applications of tarragon (<em>Artemisia dracunculus</em>) in phytotherapy will be covered in this review study. Despite the advancements in pharmaceuticals, herbal remedies continue to be vital, especially in areas where access to modern therapy is limited. In addition, the antibacterial qualities of Tarragon plant extracts and their innovative extraction techniques are described in this review article.</div></div><div><h3>Methods</h3><div>A thorough examination of the literature looked at the chemical composition, historical uses, and modern extraction techniques of tarragon (<em>A. dracunculus</em>). The extraction techniques, such as the in-syringe reversed dispersive liquid-liquid microextraction (IS-R-DLLME), ultrasound-assisted extraction (UAE), deep eutectic solvents (DES), and pressurised liquid extraction (PLE), and the methods of review analysis the antibacterial properties of tarragon (<em>A. dracunculus</em>) extracts against dangerous microbes.</div></div><div><h3>Results</h3><div>Both Gram-positive and Gram-negative bacteria can be effectively resistant by tarragon (<em>A. dracunculus</em>) essential oils and extracts. Also the primary bioactive components were limonene, methyl eugenol, and estragole. The yield and purity of bioactive components were enhanced by novel extraction techniques such as IS-R-DLLME and UAE. At minimum inhibitory concentrations (MIC). Therefore, the essential oils demonstrated strong antibacterial action against <em>Escherichia coli</em> and <em>Staphylococcus aureus.</em></div></div><div><h3>Discussion/Conclusions</h3><div>The tarragon (<em>A. dracunculus</em>) plant may be regarded as a potent natural antibacterial agent, especially for antibiotic-resistant illnesses. By combining traditional botanical knowledge with contemporary extraction methods, new medicinal compounds can be created. This study highlighted the need to explore the synergistic effects of tarragon's bioactive components and improve extraction methods in order to optimise therapeutic advantages. Ultimately, tarragon (<em>A. dracunculus</em>) may help antibiotic resistance and microbial illnesses.</div></div>","PeriodicalId":56077,"journal":{"name":"Journal of Herbal Medicine","volume":"50 ","pages":"Article 100989"},"PeriodicalIF":2.2,"publicationDate":"2025-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143378380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-01DOI: 10.1016/j.hermed.2024.100971
Yafang Guo , Hong Lu , Jialin Zhu , Jianjun Feng , Yonggang Gu , Li Ma , Yunsheng Huang , Chengxing Xu , Xinge Feng , Zhongqiu Wen , Lili Gao , Wujun Xiong , Xuhui Bao , Changming Zhang , Yipeng Zeng
Introduction
The efficacy of Chinese herbal medicine (CHM) in treating infection with the Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains to be investigated. This study aimed to assess the efficacy of CHM in COVID-19 Omicron patients.
Methods
Inpatients aged 18 years or older were divided into two groups based on their treatment: Western medicine group (WMG) and CHM group (CHMG). Demographic and COVID-19-related outcome data of the inpatients were collected. We analyzed negative conversion time, hospital stay, and clinical outcomes.
Results
The Asymptomatic Type: Negative conversion time significantly decreased in the CHMG compared with that in the WMG (3.0 [range: 2.0–7.0] days vs 5.0 [range: 3.0–9.0] days, P < 0.01). The hospital stay of the CHMG significantly decreased compared with that of the WMG (6.0 [range: 3.0–11.0] days vs 9.0 [range: 6.0–13.0] days, P < 0.01). The group was independently associated with negative conversion time (P < 0.01). The Mild/Moderate type: Negative conversion time significantly decreased in the CHMG compared with the WMG (6.0 [range: 2.0–11.0] days vs 8.0 [range: 3.0–12.0] days, P < 0.01). The hospital stay of the CHMG significantly decreased compared with that of the WMG (9.0 [range: 5.0–14.0] days vs 11.0 [range: 7.0–16.0] days, P < 0.01).
Conclusion
We found that the use of the JingYinGuBiao formula in Asymptomatic type patients and the JingYinQinHua formula in Mild/Moderate type patients is one of the most effective ways of treating SARS-CoV-2 Omicron infection because it could shorten negative conversion time and hospital stay.
中药治疗严重急性呼吸综合征冠状病毒2 （SARS-CoV-2）欧米克隆变异感染的疗效尚待研究。本研究旨在评估CHM对COVID-19 Omicron患者的疗效。方法将18岁及以上患者按治疗方式分为西药组（WMG）和中药组（CHMG）。收集住院患者的人口学和covid -19相关结局数据。我们分析了负转化时间、住院时间和临床结果。结果无症状型：阴性转化时间CHMG组显著低于WMG组（3.0[范围：2.0-7.0]d vs 5.0[范围：3.0 - 9.0]d）；0.01)。与WMG组相比，CHMG组住院时间明显缩短（6.0[范围：3.0-11.0]天vs 9.0[范围：6.0 - 13.0]天），P <；0.01)。组与负转换时间独立相关(P <；0.01)。轻度/中度：与WMG相比，CHMG的负转化时间显著缩短(6.0[范围：2.0-11.0]天vs 8.0[范围：3.0-12.0]天，P <；0.01)。与WMG组相比，CHMG组住院时间明显缩短(9.0[范围：5.0-14.0]d vs 11.0[范围：7.0-16.0]d, P <；0.01)。结论在无症状型患者中应用经银骨标方，在轻、中度患者中应用经银芩化方可缩短阴性转化时间和住院时间，是治疗SARS-CoV-2 Omicron感染最有效的方法之一。
{"title":"Clinical outcomes of hospitalised COVID-19 Omicron patients treated with traditional Chinese Medicine: A Retrospective Studymedicine: a retrospective study of a large medical centre in Shanghai, China","authors":"Yafang Guo , Hong Lu , Jialin Zhu , Jianjun Feng , Yonggang Gu , Li Ma , Yunsheng Huang , Chengxing Xu , Xinge Feng , Zhongqiu Wen , Lili Gao , Wujun Xiong , Xuhui Bao , Changming Zhang , Yipeng Zeng","doi":"10.1016/j.hermed.2024.100971","DOIUrl":"10.1016/j.hermed.2024.100971","url":null,"abstract":"<div><h3>Introduction</h3><div>The efficacy of Chinese herbal medicine (CHM) in treating infection with the Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains to be investigated. This study aimed to assess the efficacy of CHM in COVID-19 Omicron patients.</div></div><div><h3>Methods</h3><div>Inpatients aged 18 years or older were divided into two groups based on their treatment: Western medicine group (WMG) and CHM group (CHMG). Demographic and COVID-19-related outcome data of the inpatients were collected. We analyzed negative conversion time, hospital stay, and clinical outcomes.</div></div><div><h3>Results</h3><div>The Asymptomatic Type: Negative conversion time significantly decreased in the CHMG compared with that in the WMG (3.0 [range: 2.0–7.0] days vs 5.0 [range: 3.0–9.0] days, <em>P</em> < 0.01). The hospital stay of the CHMG significantly decreased compared with that of the WMG (6.0 [range: 3.0–11.0] days vs 9.0 [range: 6.0–13.0] days, <em>P</em> < 0.01). The group was independently associated with negative conversion time (<em>P</em> < 0.01). The Mild/Moderate type: Negative conversion time significantly decreased in the CHMG compared with the WMG (6.0 [range: 2.0–11.0] days vs 8.0 [range: 3.0–12.0] days, <em>P</em> < 0.01). The hospital stay of the CHMG significantly decreased compared with that of the WMG (9.0 [range: 5.0–14.0] days vs 11.0 [range: 7.0–16.0] days, <em>P</em> < 0.01).</div></div><div><h3>Conclusion</h3><div>We found that the use of the JingYinGuBiao formula in Asymptomatic type patients and the JingYinQinHua formula in Mild/Moderate type patients is one of the most effective ways of treating SARS-CoV-2 Omicron infection because it could shorten negative conversion time and hospital stay.</div></div>","PeriodicalId":56077,"journal":{"name":"Journal of Herbal Medicine","volume":"48 ","pages":"Article 100971"},"PeriodicalIF":2.2,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142759628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-01DOI: 10.1016/j.hermed.2024.100970
Xinwen Zhu , Xue Geng , Qi Gao , Ping Wang , Dianhua Shi , Yuecheng Liu , Qiang Zhang , Yanpeng Dai , Qian Zhou
Introduction
This review aims to provide a systematic summary of the chemical constituents, pharmacological effects, traditional use, clinical applications and quality control of acrid Chinese medicines to provide a reference for in-depth research and product development of acrid Chinese medicinal volatile oils.
Methods
In this study, the database of CNKI, Web of Science and PubMed were used to search for information on acrid Chinese medicines using the name (Latin name) and ‘volatile oil’.
Results
This review summarises and analyzes the chemical composition and pharmacological effect of 126 kinds of eight types of acrid Chinese medicines. The results show that the main components of the volatile oils used in acrid Chinese medicines are terpenoids and terpenes, followed by alcohols and esters. These components have been used in medicine because of their pharmacological activities.
Conclusions
Volatile oils have a broad spectrum of pharmacological activities. However, due to the complex composition and unstable quality of volatile oils, the wider application of volatile oils is limited; the current quality specifications at all levels lack research on the composition limits and standards of volatile oils. Therefore, establishing corresponding quality control standards should be the key research direction for volatile oils in the future.
本文对辛辣类中药的化学成分、药理作用、传统用法、临床应用和质量控制等方面进行了系统的综述，为辛辣类中药挥发油的深入研究和产品开发提供参考。方法利用中国知网（CNKI）、Web of Science和PubMed数据库检索以“挥发油”和“拉丁文”命名的辛辣类中药信息。结果对8类126种辛辣类中药的化学成分和药理作用进行了综述和分析。结果表明，辛辣中药挥发油的主要成分为萜类和萜烯类，其次为醇类和酯类。这些成分因其药理活性而被用于医学。结论挥发油具有广谱的药理活性。然而，由于挥发油成分复杂，质量不稳定，限制了挥发油的广泛应用；目前各级质量规范缺乏对挥发油成分限量和标准的研究。因此，建立相应的质量控制标准应是今后挥发油的重点研究方向。
{"title":"Research progress and modern application analysis of chemical constituents and pharmacological effects of volatile oils in acrid Chinese medicines","authors":"Xinwen Zhu , Xue Geng , Qi Gao , Ping Wang , Dianhua Shi , Yuecheng Liu , Qiang Zhang , Yanpeng Dai , Qian Zhou","doi":"10.1016/j.hermed.2024.100970","DOIUrl":"10.1016/j.hermed.2024.100970","url":null,"abstract":"<div><h3>Introduction</h3><div>This review aims to provide a systematic summary of the chemical constituents, pharmacological effects, traditional use, clinical applications and quality control of acrid Chinese medicines to provide a reference for in-depth research and product development of acrid Chinese medicinal volatile oils.</div></div><div><h3>Methods</h3><div>In this study, the database of CNKI, Web of Science and PubMed were used to search for information on acrid Chinese medicines using the name (Latin name) and ‘volatile oil’.</div></div><div><h3>Results</h3><div>This review summarises and analyzes the chemical composition and pharmacological effect of 126 kinds of eight types of acrid Chinese medicines. The results show that the main components of the volatile oils used in acrid Chinese medicines are terpenoids and terpenes, followed by alcohols and esters. These components have been used in medicine because of their pharmacological activities.</div></div><div><h3>Conclusions</h3><div>Volatile oils have a broad spectrum of pharmacological activities. However, due to the complex composition and unstable quality of volatile oils, the wider application of volatile oils is limited; the current quality specifications at all levels lack research on the composition limits and standards of volatile oils. Therefore, establishing corresponding quality control standards should be the key research direction for volatile oils in the future.</div></div>","PeriodicalId":56077,"journal":{"name":"Journal of Herbal Medicine","volume":"48 ","pages":"Article 100970"},"PeriodicalIF":2.2,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142748507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-01DOI: 10.1016/j.hermed.2024.100965
Kátia Andrea de Menezes Torres , Sônia Maria Rolim Rosa Lima , Maria Thereza Gamberini , Domingos Sávio Rodrigues , Pedro Ismael Silva Junior
Introduction
Maternal colonisation with Streptococcus agalactiae, or Group B Streptococcus (GBS), during pregnancy increases the risk of neonatal infection through vertical transmission from the mother to the foetus, either before or during labour. This study aimed to evaluate the antimicrobial activity of the Sep-Pak 80% (SP80) fraction derived from Allium sativum L. and its synergistic potential with antibiotics against GBS strains.
Methods
Antimicrobial activity and potential synergism were assessed via broth microdilution and disk diffusion assays. Fifty-five clinical isolates and one American type culture collection (ATCC) strain of GBS were tested with the disk diffusion method to assess the combination of the SP80 fraction with ampicillin and penicillin G. A broth microdilution assay was performed on one ATCC strain.
Results
The minimum inhibitory concentrations of SP80, ampicillin, and penicillin G against Streptococcus agalactiae (ATCC 12386) were 5 mg/mL, 0.01 µg/mL, and 0.06 µg/mL, respectively. The combination of SP80 with antibiotics, assessed through broth microdilution, demonstrated an additive effect. Statistical analysis revealed that the mean inhibition zone for ampicillin, when combined with the SP80 fraction using the disk diffusion method, was greater than that for ampicillin alone, although the difference was not statistically significant. For penicillin G, the mean remained unchanged when it was combined with SP80. The inhibition zones of the isolated antibiotics revealed that the tested strains were more resistant to penicillin G than to ampicillin.
Conclusions
The SP80 fraction exhibits antimicrobial activity against GBS. When combined with antibiotics, it has an additive effect, suggesting that this approach could be promising for combating GBS infections.
{"title":"Group B Strep During Pregnancy and Allium sativum L.","authors":"Kátia Andrea de Menezes Torres , Sônia Maria Rolim Rosa Lima , Maria Thereza Gamberini , Domingos Sávio Rodrigues , Pedro Ismael Silva Junior","doi":"10.1016/j.hermed.2024.100965","DOIUrl":"10.1016/j.hermed.2024.100965","url":null,"abstract":"<div><h3>Introduction</h3><div>Maternal colonisation with <em>Streptococcus agalactiae</em>, or Group B <em>Streptococcus</em> (<strong>GBS</strong>), during pregnancy increases the risk of neonatal infection through vertical transmission from the mother to the foetus, either before or during labour. This study aimed to evaluate the antimicrobial activity of the Sep-Pak 80% (<strong>SP80</strong>) fraction derived from <em>Allium sativum</em> L. and its synergistic potential with antibiotics against GBS strains.</div></div><div><h3>Methods</h3><div>Antimicrobial activity and potential synergism were assessed via broth microdilution and disk diffusion assays. Fifty-five clinical isolates and one American type culture collection (ATCC) strain of GBS were tested with the disk diffusion method to assess the combination of the SP80 fraction with ampicillin and penicillin G. A broth microdilution assay was performed on one ATCC strain.</div></div><div><h3>Results</h3><div>The minimum inhibitory concentrations of SP80, ampicillin, and penicillin G against <em>Streptococcus agalactiae</em> (ATCC 12386) were 5 mg/mL, 0.01 µg/mL, and 0.06 µg/mL, respectively. The combination of SP80 with antibiotics, assessed through broth microdilution, demonstrated an additive effect. Statistical analysis revealed that the mean inhibition zone for ampicillin, when combined with the SP80 fraction using the disk diffusion method, was greater than that for ampicillin alone, although the difference was not statistically significant. For penicillin G, the mean remained unchanged when it was combined with SP80. The inhibition zones of the isolated antibiotics revealed that the tested strains were more resistant to penicillin G than to ampicillin.</div></div><div><h3>Conclusions</h3><div>The SP80 fraction exhibits antimicrobial activity against GBS. When combined with antibiotics, it has an additive effect, suggesting that this approach could be promising for combating GBS infections.</div></div>","PeriodicalId":56077,"journal":{"name":"Journal of Herbal Medicine","volume":"48 ","pages":"Article 100965"},"PeriodicalIF":2.2,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142748505","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Non-Alcoholic Fatty Liver Disease (NAFLD) is a prevalent liver disorder and a leading cause of elevated liver enzymes. Previous research indicates that a diet rich in polyunsaturated fatty acids (PUFAs) can alleviate liver insulin resistance. This study investigates the therapeutic effects of flaxseed oil, a primary PUFA source, on NAFLD treatment.
Methods
In a randomized clinical trial comprising 60 NAFLD patients diagnosed with NAFLD of grades 1, 2, and 3, participants were assigned to either a flaxseed oil capsule or a placebo group, for a total duration of 2 months.
Results
Before the intervention, both groups showed no significant differences in examined parameters. However, after the intervention, the flaxseed oil group exhibited significant improvements in Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), fasting blood sugar (FBS), and total bilirubin, compared to the placebo group. Specifically, reductions were observed in AST (P = 0.010), ALT (P = 0.047), ALP (P < 0.001), FBS (P = 0.016), and total bilirubin (P = 0.004).
Conclusions
These findings suggest that flaxseed oil may hold promise as a therapeutic intervention for NAFLD, highlighting its potential in managing liver disease and metabolic parameters.
{"title":"The efficacy of flaxseed oil on non-alcoholic fatty liver disease: a randomised controlled trial","authors":"Ali Beheshti Namdar , Delaram Omidvar , Forouzan Amerizadeh , Mona Kabiri , Hediyeh Beheshti Namdar , Sahar Ravanshad","doi":"10.1016/j.hermed.2024.100967","DOIUrl":"10.1016/j.hermed.2024.100967","url":null,"abstract":"<div><h3>Introduction</h3><div>Non-Alcoholic Fatty Liver Disease (NAFLD) is a prevalent liver disorder and a leading cause of elevated liver enzymes. Previous research indicates that a diet rich in polyunsaturated fatty acids (PUFAs) can alleviate liver insulin resistance. This study investigates the therapeutic effects of flaxseed oil, a primary PUFA source, on NAFLD treatment.</div></div><div><h3>Methods</h3><div>In a randomized clinical trial comprising 60 NAFLD patients diagnosed with NAFLD of grades 1, 2, and 3, participants were assigned to either a flaxseed oil capsule or a placebo group, for a total duration of 2 months.</div></div><div><h3>Results</h3><div>Before the intervention, both groups showed no significant differences in examined parameters. However, after the intervention, the flaxseed oil group exhibited significant improvements in Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), fasting blood sugar (FBS), and total bilirubin, compared to the placebo group. Specifically, reductions were observed in AST (<em>P</em> = 0.010), ALT (<em>P</em> = 0.047), ALP (<em>P</em> < 0.001), FBS (<em>P</em> = 0.016), and total bilirubin (<em>P</em> = 0.004).</div></div><div><h3>Conclusions</h3><div>These findings suggest that flaxseed oil may hold promise as a therapeutic intervention for NAFLD, highlighting its potential in managing liver disease and metabolic parameters.</div></div>","PeriodicalId":56077,"journal":{"name":"Journal of Herbal Medicine","volume":"48 ","pages":"Article 100967"},"PeriodicalIF":2.2,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142748506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Evidence has highlighted neuroprotective effects of saffron in animal models of Parkinson’s disease (PD). The present study investigated the efficacy and safety of add-on saffron on motor and depressive symptoms of patients with PD.
Methods
This study was an 8-week, randomized, double-blind, and parallel-group clinical trial. Known cases of PD with depression were randomized to receive either a routine treatment (levodopa or levodopa-equivalent dose of a dopamine agonist) plus saffron capsule (15 mg bid) or routine treatment plus placebo. All participants were assessed using the Hamilton Depression Rating Scale (HAMD), Geriatric Depression Scale-30 (GDS-30), item 3 of Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part 1, MDS-UPDRS part 3, and H and Y scale at baseline and at week 8.
Results
A total of 52 patients (25 in saffron and 27 in placebo groups) were included. Our results demonstrated that saffron could not improve motor symptoms of PD patients (F=0.53, df=1, p=0.424). However, repeated-measures analysis showed a significant effect of time treatment (F=8.24, df=1, p=0.006) on HAMD scores, indicating a greater improvement of depressive symptoms in saffron compared to placebo groups. Our study showed nonsignificant findings regarding the secondary outcome measures (GDS-30, item 3 of MDS-UPDRS part 1, and H and Y scale). We showed that treatment with saffron is safe in PD.
Conclusion
We substantiated that add-on treatment with saffron significantly improved depression, but not motor symptoms, in PD. Further trials with larger sample sizes and longer follow-ups are needed to confirm our findings.
目的有证据表明藏红花在帕金森病（PD）动物模型中具有神经保护作用。本研究调查了添加藏红花对帕金森病患者运动症状和抑郁症状的疗效和安全性。方法本研究是一项为期 8 周的随机、双盲、平行组临床试验。已知的伴有抑郁的帕金森氏症病例被随机分配接受常规治疗（左旋多巴或左旋多巴等效剂量的多巴胺激动剂）加藏红花胶囊（15 毫克 bid）或常规治疗加安慰剂。所有参与者在基线和第8周时均接受了汉密尔顿抑郁量表（HAMD）、老年抑郁量表-30（GDS-30）、运动障碍协会统一帕金森病评分量表（MDS-UPDRS）第1部分第3项、MDS-UPDRS第3部分以及H和Y量表的评估。结果表明，藏红花不能改善帕金森病患者的运动症状（F=0.53，df=1，P=0.424）。然而，重复测量分析表明，时间×治疗（F=8.24，df=1，p=0.006）对HAMD评分有显著影响，表明藏红花组比安慰剂组对抑郁症状的改善更大。我们的研究显示，次要结果测量（GDS-30、MDS-UPDRS 第 1 部分第 3 项以及 H 和 Y 量表）的结果不显著。结论我们证实了藏红花附加治疗能显著改善帕金森病患者的抑郁，但不能改善运动症状。要证实我们的研究结果，还需要进行样本量更大、随访时间更长的进一步试验。
{"title":"Evaluating efficacy and safety of Saffron add-on treatment in improvement of motor and depressive symptoms of patients with Parkinson’s disease: A randomized, double-blind, placebo-controlled clinical trial","authors":"Vahirezad Lalezari , Vajiheh Aghamollaii , Ahmadreza Moslehi , Amir Najafi , Mohammadamin Parsaei , Alireza Beikmarzehei , Hossein Sanjari Moghaddam , Amir Hossein Abdolghaffari , Shahin Akhondzadeh","doi":"10.1016/j.hermed.2024.100968","DOIUrl":"10.1016/j.hermed.2024.100968","url":null,"abstract":"<div><h3>Aim</h3><div>Evidence has highlighted neuroprotective effects of saffron in animal models of Parkinson’s disease (PD). The present study investigated the efficacy and safety of add-on saffron on motor and depressive symptoms of patients with PD.</div></div><div><h3>Methods</h3><div>This study was an 8-week, randomized, double-blind, and parallel-group clinical trial. Known cases of PD with depression were randomized to receive either a routine treatment (levodopa or levodopa-equivalent dose of a dopamine agonist) plus saffron capsule (15 mg bid) or routine treatment plus placebo. All participants were assessed using the Hamilton Depression Rating Scale (HAMD), Geriatric Depression Scale-30 (GDS-30), item 3 of Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part 1, MDS-UPDRS part 3, and H and Y scale at baseline and at week 8.</div></div><div><h3>Results</h3><div>A total of 52 patients (25 in saffron and 27 in placebo groups) were included. Our results demonstrated that saffron could not improve motor symptoms of PD patients (F=0.53, df=1, p=0.424). However, repeated-measures analysis showed a significant effect of time <span><math><mo>×</mo></math></span> treatment (F=8.24, df=1, p=0.006) on HAMD scores, indicating a greater improvement of depressive symptoms in saffron compared to placebo groups. Our study showed nonsignificant findings regarding the secondary outcome measures (GDS-30, item 3 of MDS-UPDRS part 1, and H and Y scale). We showed that treatment with saffron is safe in PD.</div></div><div><h3>Conclusion</h3><div>We substantiated that add-on treatment with saffron significantly improved depression, but not motor symptoms, in PD. Further trials with larger sample sizes and longer follow-ups are needed to confirm our findings.</div></div>","PeriodicalId":56077,"journal":{"name":"Journal of Herbal Medicine","volume":"48 ","pages":"Article 100968"},"PeriodicalIF":2.2,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142662802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号